MRTX
Mirati Therapeutics, Inc. (MRTX)
$91.50.13%▲
Market is closedMarket is closed – opens on 8 PM, 02 Dec 2022
– opens on 8 PM, 02 Dec 2022
Key Stats
$90.47
Day's Range
$94.6
$32.96
52-Week Range
$154.17
| Returns | |
| 1 month return | 40.79% |
| 3 month return | 12.92% |
| 1 year return | 33.24% |
| 5 year return | 468.32% |
Company Information
Mirati Therapeutics is a late-stage biotechnology company whose mission is to discover, design and deliver breakthrough therapies to transform the lives of patients with cancer and their loved ones. The company is relentlessly focused on bringing forward therapies that address areas of high unmet need, including lung cancer, and advancing a pipeline of novel therapeutics targeting the genetic and immunological drivers of cancer. Mirati is using its scientific expertise to develop novel solutions in two registration-enabling programs: adagrasib (MRTX849), an investigational small molecule, potent and selective KRAS G12C inhibitor, as monotherapy and in combination with other agents, and sitravatinib, an investigational spectrum-selective inhibitor of receptor tyrosine kinases in combination with checkpoint inhibitor therapies. Mirati is also advancing its differentiated preclinical portfolio, including MRTX1133, an investigational KRAS G12D inhibitor, and other oncology discovery programs. Unified for patients, Mirati's vision is to unlock the science behind the promise of a life beyond cancer.
| Organization | Mirati Therapeutics, Inc. |
| Employees | 413 |
| CEO | Mr. David D. Meek |
| Industry | Health Technology |
Analyst Recommendation
based on 15 analysts ratings
Buy
73%
Buy
20%
Hold
6%
Sell
Based on 15 Wall street analysts offering stock ratings for Mirati Therapeutics, Inc.(by analysts ranked 0 to 5 stars)
Analyst Forecast
What analysts predicted
Upside of 26.44%Current
$91.5
Target
$115.69
Recommendation Trend
Based on 15 analyst
| Current | 1M Ago | 3M Ago | |
| Buy | 11 | 19 | 18 |
| Hold | 3 | 4 | 4 |
| Sell | 1 | 0 | 0 |
| Consensus | BUY | BUY | BUY |
Company Financials
Highlights
| Market Capitalization | 5.3B |
| Book Value | $19.61 |
| Dividend Share | 0.0 |
| Dividend Yield | 0.0% |
| Earnings Per Share (EPS) | -11.96 |
| PEG Ratio | 0.0 |
| Wall Street Target Price | 115.69 |
Valuation
| Trailing PE | 0.0 |
| Forward PE | 0.0 |
| Price/Book (mrq) | 4.88 |
| Enterprise Value | 4.4B |
| Enterprise Value/Revenue | 369.43 |
| Enterprise Value/Ebitda | -5.87 |
Technicals
| Beta | 0.83 |
| 50 Day MA | 70.67 |
| 200 Day MA | 72.12 |
Institutional Holdings
venBio Select Advisor LLC
9.64%
Vanguard Group Inc
8.21%
Wellington Management Company LLP
6.03%
Aviva Holdings Ltd
5.45%
Perceptive Advisors LLC
4.98%
FMR Inc
3.49%
Discover more
Frequently Asked Questions
What is Mirati Therapeutics, Inc. share price today?
Can Indians buy Mirati Therapeutics, Inc. shares?
How can I buy Mirati Therapeutics, Inc. shares from India?
Can Fractional shares of Mirati Therapeutics, Inc. be purchased?
What are the documents required to start investing in Mirati Therapeutics, Inc. stocks?
What are today’s High and Low prices of Mirati Therapeutics, Inc.?
What are today’s traded volumes of Mirati Therapeutics, Inc.?
What is today’s market capitalisation of Mirati Therapeutics, Inc.?
What is the 52 Week High and Low Range of Mirati Therapeutics, Inc.?
How much percentage Mirati Therapeutics, Inc. is down from its 52 Week High?
How much percentage Mirati Therapeutics, Inc. is up from its 52 Week low?
What are the historical returns of Mirati Therapeutics, Inc.?
Who is the Chief Executive Officer (CEO) of Mirati Therapeutics, Inc.?
Trading and brokerage services provided by
Banking and Remittance services provided by
Technology services provided by : Finzoomers Services Private Limited
Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*